The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5-Reference-Cited by-同舟云学术

The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5

Published:2023-12 Issue:12 Volume:55 Page:1658-1666
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Bouhnik Yoram^ORCID,Carbonnel Franck,Fumery Mathurin,Flamant Mathurin,Buisson Anne,Camoin Armelle,Addison Janet

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference36 articles.

1. Dramatic increase in incidence of ulcerative colitis and Crohn's disease (1988–2011): a population-based study of french adolescents;Ghione;Off J Am Coll Gastroenterol,2018

2. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;Alatab;Lancet Gastroenterol Hepatol,2020

3. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

4. 01-Lessentiel-Maladie-de-Crohn.pdf [Internet]. [cited 2022 Feb 2]. Available from: https://www.afa.asso.fr/wp-content/uploads/2020/03/01-Lessentiel-Maladie-de-Crohn.pdf.

5. 02-Lessentiel-Rectocolite.pdf [Internet]. [cited 2022 Feb 2]. Available from: https://www.afa.asso.fr/wp-content/uploads/2020/03/02-Lessentiel-Rectocolite.pdf.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-11-23